The Insight into the Role of Leptin and Its Receptor in Heart Failure with Preserved Ejection Fraction
DOI:
https://doi.org/10.12775/QS.2024.35.56489Keywords
leptin, Heart failure with preserved ejection fraction, inflammation, leptin receptor, diastolic dysfunction, obesityAbstract
Heart failure with preserved ejection fraction (HFpEF) is a complex clinical syndrome with a multifactorial pathogenesis. Leptin, a hormone produced by adipose tissue, plays a key role in regulating energy balance, metabolism, and inflammatory processes. Its impact on the cardiovascular system is dualistic: on one hand, leptin can contribute to the development of HFpEF by promoting inflammation and metabolic dysfunction; on the other hand, it may exert protective effects by reducing body weight and enhancing metabolic functions. This literature review examines current data on leptin's role in HFpEF, exploring both its detrimental and beneficial effects. The objective is to elucidate the mechanisms through which leptin influences the onset and progression of HFpEF, potentially guiding the development of more targeted therapeutic strategies.
References
Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2014 Sep 24;11(9):507–15.
Nandini Nair. Epidemiology and pathogenesis of heart failure with preserved ejection fraction. Rev Cardiovasc Med. 2020;21(4):531.
Obokata M, Reddy YNV, Borlaug BA. Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction. JACC Cardiovasc Imaging. 2020 Jan;13(1):245–57.
Basu S, Yu H, Murrow JR, Hallow KM. Understanding heterogeneous mechanisms of heart failure with preserved ejection fraction through cardiorenal mathematical modeling. PLoS Comput Biol. 2023 Nov 13;19(11):e1011598.
Harrod KK, Rogers JL, Feinstein JA, Marsden AL, Schiavazzi DE. Predictive Modeling of Secondary Pulmonary Hypertension in Left Ventricular Diastolic Dysfunction. Front Physiol. 2021 Jul 1;12.
Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Christensen L, Davies M, et al. Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype. JACC Heart Fail. 2023 Aug;11(8):1000–10.
Butler J, Shah SJ, Petrie MC, Borlaug BA, Abildstrøm SZ, Davies MJ, et al. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. The Lancet. 2024 Apr;403(10437):1635–48.
Verma S, Petrie MC, Borlaug BA, Butler J, Davies MJ, Kitzman DW, et al. Inflammation in Obesity-Related HFpEF. J Am Coll Cardiol. 2024 Oct;84(17):1646–62.
Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK, et al. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. New England Journal of Medicine. 2024 Apr 18;390(15):1394–407.
Wang M, Li Y, Li S, Lv J. Endothelial Dysfunction and Diabetic Cardiomyopathy. Front Endocrinol (Lausanne). 2022 Apr 7;13.
Jankauskas SS, Kansakar U, Varzideh F, Wilson S, Mone P, Lombardi A, et al. Heart failure in diabetes. Metabolism. 2021 Dec;125:154910.
Ottosen CI, Nadruz W, Inciardi RM, Johansen ND, Fudim M, Biering-Sørensen T. Diastolic dysfunction in hypertension: a comprehensive review of pathophysiology, diagnosis, and treatment. Eur Heart J Cardiovasc Imaging. 2024 Oct 30;25(11):1525–36.
de Simone G, Mancusi C. Diastolic function in chronic kidney disease. Clin Kidney J. 2023 Oct 31;16(11):1925–35.
Momot K, Wojciechowska M, Krauz K, Czarzasta K, Puchalska L, Zarębiński M, et al. Endoplasmic reticulum stress and expression of nitric oxide synthases in heart failure with preserved and with reduced ejection fraction — pilot study. Cardiol J. 2024 Oct 3;
JÉQUIER E. Leptin Signaling, Adiposity, and Energy Balance. Ann N Y Acad Sci. 2002 Jun 24;967(1):379–88.
Vilariño-García T, Polonio-González M, Pérez-Pérez A, Ribalta J, Arrieta F, Aguilar M, et al. Role of Leptin in Obesity, Cardiovascular Disease, and Type 2 Diabetes. Int J Mol Sci. 2024 Feb 16;25(4):2338.
Katsiki N, Mikhailidis DP, Banach M. Leptin, cardiovascular diseases and type 2 diabetes mellitus. Acta Pharmacol Sin. 2018 Jul 7;39(7):1176–88.
Abella V, Scotece M, Conde J, Pino J, Gonzalez-Gay MA, Gómez-Reino JJ, et al. Leptin in the interplay of inflammation, metabolism and immune system disorders. Nat Rev Rheumatol. 2017 Feb 5;13(2):100–9.
Scotece M, Conde J, López V, Lago F, Pino J, Gómez‐Reino JJ, et al. Adiponectin and Leptin: New Targets in Inflammation. Basic Clin Pharmacol Toxicol. 2014 Jan 26;114(1):97–102.
Hou N, Luo J. Leptin and cardiovascular diseases. Clin Exp Pharmacol Physiol. 2011 Dec 27;38(12):905–13.
Münzberg H, Heymsfield SB, Berthoud HR, Morrison CD. History and future of leptin: Discovery, regulation and signaling. Metabolism. 2024 Dec;161:156026.
Obradovic M, Sudar-Milovanovic E, Soskic S, Essack M, Arya S, Stewart AJ, et al. Leptin and Obesity: Role and Clinical Implication. Front Endocrinol (Lausanne). 2021 May 18;12.
Izquierdo AG, Crujeiras AB, Casanueva FF, Carreira MC. Leptin, Obesity, and Leptin Resistance: Where Are We 25 Years Later? Nutrients. 2019 Nov 8;11(11):2704.
Münzberg H, Morrison CD. Structure, production and signaling of leptin. Metabolism. 2015 Jan;64(1):13–23.
Meek TH, Morton GJ. The role of leptin in diabetes: metabolic effects. Diabetologia. 2016 May 11;59(5):928–32.
Zhao S, Zhu Y, Schultz RD, Li N, He Z, Zhang Z, et al. Partial Leptin Reduction as an Insulin Sensitization and Weight Loss Strategy. Cell Metab. 2019 Oct;30(4):706-719.e6.
Wang C, Chang L, Wang J, Xia L, Cao L, Wang W, et al. Leptin and risk factors for atherosclerosis: A review. Medicine. 2023 Nov 17;102(46):e36076.
Beltowski J. Leptin and atherosclerosis. Atherosclerosis. 2006 Nov;189(1):47–60.
Yadav A, Kataria MA, Saini V, Yadav A. Role of leptin and adiponectin in insulin resistance. Clinica Chimica Acta. 2013 Feb;417:80–4.
Haynes WG. Interaction between leptin and sympathetic nervous system in hypertension. Curr Hypertens Rep. 2000 May;2(3):311–8.
El Meouchy P, Wahoud M, Allam S, Chedid R, Karam W, Karam S. Hypertension Related to Obesity: Pathogenesis, Characteristics and Factors for Control. Int J Mol Sci. 2022 Oct 14;23(20):12305.
Saxton RA, Caveney NA, Moya-Garzon MD, Householder KD, Rodriguez GE, Burdsall KA, et al. Structural insights into the mechanism of leptin receptor activation. Nat Commun. 2023 Mar 31;14(1):1797.
Abd El-Aziz TA, Mohamed RH, Mohamed RH, Pasha HF. Leptin, leptin gene and leptin receptor gene polymorphism in heart failure with preserved ejection fraction. Heart Vessels. 2012 May 17;27(3):271–9.
Matsui H, Motooka M, Koike H, Inoue M, Iwasaki T, Suzuki T, et al. Ischemia/reperfusion in rat heart induces leptin and leptin receptor gene expression. Life Sci. 2007 Jan;80(7):672–80.
Ahima RS, Flier JS. Leptin. Annu Rev Physiol. 2000 Mar;62(1):413–37.
Cui Q, Zhang Y, Tian N, Yang J, Ya D, Xiang W, et al. Leptin Promotes Angiogenesis via Pericyte STAT3 Pathway upon Intracerebral Hemorrhage. Cells. 2022 Sep 3;11(17):2755.
Zhang L, Wu BH, Liang TT, Liu Z, Ju W, Wang Y, et al. Leptin activates the JAK/STAT pathway to promote angiogenesis in RF/6A cells in vitro. Int J Ophthalmol. 2022 Apr 18;15(4):554–9.
Hariri M Al, Jaffa MA, Saoud R, Zhao J, Zhu R, Jaffa AA, et al. Vascular Cells Proteome Associated with Bradykinin and Leptin Inflammation and Oxidative Stress Signals. Antioxidants. 2020 Dec 9;9(12):1251.
Mao Y, Zhao K, Li P, Sheng Y. The emerging role of leptin in obesity-associated cardiac fibrosis: evidence and mechanism. Mol Cell Biochem. 2023 May 10;478(5):991–1011.
Landecho MF, Tuero C, Valentí V, Bilbao I, de la Higuera M, Frühbeck G. Relevance of Leptin and Other Adipokines in Obesity-Associated Cardiovascular Risk. Nutrients. 2019 Nov 5;11(11):2664.
Ben‐Zvi D, Savion N, Kolodgie F, Simon A, Fisch S, Schäfer K, et al. Local Application of Leptin Antagonist Attenuates Angiotensin II–Induced Ascending Aortic Aneurysm and Cardiac Remodeling. J Am Heart Assoc. 2016 May 6;5(5).
Pop C, Ștefan MG, Muntean DM, Stoicescu L, Gal AF, Kiss B, et al. Protective Effects of a Discontinuous Treatment with Alpha-Lipoic Acid in Obesity-Related Heart Failure with Preserved Ejection Fraction, in Rats. Antioxidants. 2020 Oct 31;9(11):1073.
Bogaert YE, Linas S. The role of obesity in the pathogenesis of hypertension. Nat Clin Pract Nephrol. 2009 Feb 23;5(2):101–11.
Packer M. Leptin-Aldosterone-Neprilysin Axis. Circulation. 2018 Apr 10;137(15):1614–31.
Packer M. Derangements in adrenergic–adipokine signalling establish a neurohormonal basis for obesity‐related heart failure with a preserved ejection fraction. Eur J Heart Fail. 2018 May;20(5):873–8.
Huby AC, Antonova G, Groenendyk J, Gomez-Sanchez CE, Bollag WB, Filosa JA, et al. Adipocyte-Derived Hormone Leptin Is a Direct Regulator of Aldosterone Secretion, Which Promotes Endothelial Dysfunction and Cardiac Fibrosis. Circulation. 2015 Dec;132(22):2134–45.
Schwinger RHG. Pathophysiology of heart failure. Cardiovasc Diagn Ther. 2021 Feb;11(1):263–76.
Xue B, Yu Y, Zhang Z, Guo F, Beltz TG, Thunhorst RL, et al. Leptin Mediates High-Fat Diet Sensitization of Angiotensin II–Elicited Hypertension by Upregulating the Brain Renin–Angiotensin System and Inflammation. Hypertension. 2016 May;67(5):970–6.
Alpert MA, Karthikeyan K, Abdullah O, Ghadban R. Obesity and Cardiac Remodeling in Adults: Mechanisms and Clinical Implications. Prog Cardiovasc Dis. 2018 Jul;61(2):114–23.
Momot K, Krauz K, Czarzasta K, Zarębiński M, Puchalska L, Wojciechowska M. Evaluation of Nitrosative/Oxidative Stress and Inflammation in Heart Failure with Preserved and Reduced Ejection Fraction. Int J Mol Sci. 2023 Nov 3;24(21):15944.
Momot K, Krauz K, Czarzasta K, Tomaszewski J, Dobruch J, Żera T, et al. Post-myocardial infarction heart failure and long-term high-fat diet: Cardiac endoplasmic reticulum stress and unfolded protein response in Sprague Dawley rat model. PLoS One. 2024 Sep 18;19(9):e0308833.
Paulus WJ, Tschöpe C. A Novel Paradigm for Heart Failure With Preserved Ejection Fraction. J Am Coll Cardiol. 2013 Jul;62(4):263–71.
Faxén UL, Hage C, Andreasson A, Donal E, Daubert JC, Linde C, et al. HFpEF and HFrEF exhibit different phenotypes as assessed by leptin and adiponectin. Int J Cardiol. 2017 Feb;228:709–16.
Aimo A, Castiglione V, Vergaro G, Panichella G, Senni M, Lombardi CM, et al. The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction. Heart Fail Rev. 2022 Jul 21;27(4):1165–71.
Poetsch MS, Strano A, Guan K. Role of Leptin in Cardiovascular Diseases. Front Endocrinol (Lausanne). 2020 Jun 16;11.
Slivnick J, Lampert BC. Hypertension and Heart Failure. Heart Fail Clin. 2019 Oct;15(4):531–41.
Simonds SE, Pryor JT, Ravussin E, Greenway FL, Dileone R, Allen AM, et al. Leptin Mediates the Increase in Blood Pressure Associated with Obesity. Cell. 2014 Dec;159(6):1404–16.
Schneider MP, Klingbeil AU, Schlaich MP, Langenfeld MR, Veelken R, Schmieder RE. Impaired Sodium Excretion During Mental Stress in Mild Essential Hypertension. Hypertension. 2001 Mar;37(3):923–7.
Tokuhisa H, Murai H, Okabe Y, Hamaoka T, Sugimoto H, Mukai Y, et al. Differential effects of lipophilic and hydrophilic statins on muscle sympathetic nerve activity in heart failure with preserved left ventricular ejection fraction. Autonomic Neuroscience. 2018 Sep;213:8–14.
Morgan DA, Thedens DR, Weiss R, Rahmouni K. Mechanisms mediating renal sympathetic activation to leptin in obesity. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 2008 Dec;295(6):R1730–6.
Shimada YJ. Is leptin protective against heart failure with preserved ejection fraction? A complex interrelationship among leptin, obesity, and left ventricular hypertrophy. Hypertension Research. 2019 Feb 12;42(2):141–2.
Atawia RT, Faulkner JL, Mehta V, Austin A, Jordan CR, Kennard S, et al. Endothelial leptin receptor is dispensable for leptin-induced sympatho-activation and hypertension in male mice. Vascul Pharmacol. 2022 Oct;146:107093.
Kurajoh M, Koyama H, Kadoya M, Naka M, Miyoshi A, Kanzaki A, et al. Plasma leptin level is associated with cardiac autonomic dysfunction in patients with type 2 diabetes: HSCAA study. Cardiovasc Diabetol. 2015 Dec 4;14(1):117.
Abudureyimu M, Luo X, Wang X, Sowers JR, Wang W, Ge J, et al. Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics. J Mol Cell Biol. 2022 Sep 12;14(5).
Schiattarella GG, Rodolico D, Hill JA. Metabolic inflammation in heart failure with preserved ejection fraction. Cardiovasc Res. 2021 Jan 21;117(2):423–34.
Mesquita T, Lin Y, Ibrahim A. Chronic low‐grade inflammation in heart failure with preserved ejection fraction. Aging Cell. 2021 Sep 12;20(9).
Michels da Silva D, Langer H, Graf T. Inflammatory and Molecular Pathways in Heart Failure—Ischemia, HFpEF and Transthyretin Cardiac Amyloidosis. Int J Mol Sci. 2019 May 10;20(9):2322.
Ramirez MF, Lau ES, Parekh JK, Pan AS, Owunna N, Wang D, et al. Obesity-Related Biomarkers Are Associated With Exercise Intolerance and HFpEF. Circ Heart Fail. 2023 Nov;16(11).
Ferreira JP, Claggett BL, Liu J, Sharma A, Desai AS, Anand IS, et al. High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: Findings from TOPCAT. Int J Cardiol. 2024 May;402:131818.
Berger M, März W, Niessner A, Delgado G, Kleber M, Scharnagl H, et al. IL‐6 and hsCRP predict cardiovascular mortality in patients with heart failure with preserved ejection fraction. ESC Heart Fail. 2024 Jul 14;
Wong CN, Gui XY, Rabkin SW. Myeloperoxidase, carnitine, and derivatives of reactive oxidative metabolites in heart failure with preserved versus reduced ejection fraction: A meta-analysis. Int J Cardiol. 2024 Mar;399:131657.
Ndrepepa G. Myeloperoxidase – A bridge linking inflammation and oxidative stress with cardiovascular disease. Clinica Chimica Acta. 2019 Jun;493:36–51.
Zegeye MM, Lindkvist M, Fälker K, Kumawat AK, Paramel G, Grenegård M, et al. Activation of the JAK/STAT3 and PI3K/AKT pathways are crucial for IL-6 trans-signaling-mediated pro-inflammatory response in human vascular endothelial cells. Cell Communication and Signaling. 2018 Dec 5;16(1):55.
Toldo S, Abbate A. The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases. Nat Rev Cardiol. 2024 Apr 3;21(4):219–37.
Pellegrini C, Martelli A, Antonioli L, Fornai M, Blandizzi C, Calderone V. NLRP3 inflammasome in cardiovascular diseases: Pathophysiological and pharmacological implications. Med Res Rev. 2021 Jul 18;41(4):1890–926.
Fang H yan, Zhao X ni, Zhang M, Ma Y yao, Huang J ling, Zhou P. Beneficial effects of flavonoids on cardiovascular diseases by influencing NLRP3 inflammasome. Inflammopharmacology. 2023 Aug 1;31(4):1715–29.
Toldo S, Mezzaroma E, Buckley LF, Potere N, Di Nisio M, Biondi-Zoccai G, et al. Targeting the NLRP3 inflammasome in cardiovascular diseases. Pharmacol Ther. 2022 Aug;236:108053.
Deng Y, Xie M, Li Q, Xu X, Ou W, Zhang Y, et al. Targeting Mitochondria-Inflammation Circuit by β-Hydroxybutyrate Mitigates HFpEF. Circ Res. 2021 Jan 22;128(2):232–45.
Li N, Zhou H, Wu H, Wu Q, Duan M, Deng W, et al. STING-IRF3 contributes to lipopolysaccharide-induced cardiac dysfunction, inflammation, apoptosis and pyroptosis by activating NLRP3. Redox Biol. 2019 Jun;24:101215.
Higashikuni Y, Liu W, Numata G, Tanaka K, Fukuda D, Tanaka Y, et al. NLRP3 Inflammasome Activation Through Heart-Brain Interaction Initiates Cardiac Inflammation and Hypertrophy During Pressure Overload. Circulation. 2023 Jan 24;147(4):338–55.
Trippel TD, Holzendorf V, Halle M, Gelbrich G, Nolte K, Duvinage A, et al. Ghrelin and hormonal markers under exercise training in patients with heart failure with preserved ejection fraction: results from the Ex‐DHF pilot study. ESC Heart Fail. 2017 Feb 31;4(1):56–65.
Ayoub KF, Pothineni NVK, Rutland J, Ding Z, Mehta JL. Immunity, Inflammation, and Oxidative Stress in Heart Failure: Emerging Molecular Targets. Cardiovasc Drugs Ther. 2017 Dec 27;31(5–6):593–608.
Abe Y, Ono K, Kawamura T, Wada H, Kita T, Shimatsu A, et al. Leptin induces elongation of cardiac myocytes and causes eccentric left ventricular dilatation with compensation. American Journal of Physiology-Heart and Circulatory Physiology. 2007 May;292(5):H2387–96.
Hamo CE, DeJong C, Hartshorne-Evans N, Lund LH, Shah SJ, Solomon S, et al. Heart failure with preserved ejection fraction. Nat Rev Dis Primers. 2024 Aug 14;10(1):55.
Fontes-Carvalho R, Pimenta J, Bettencourt P, Leite-Moreira A, Azevedo A. Association between plasma leptin and adiponectin levels and diastolic function in the general population. Expert Opin Ther Targets. 2015 Oct 3;19(10):1283–91.
Sawaki D, Czibik G, Pini M, Ternacle J, Suffee N, Mercedes R, et al. Visceral Adipose Tissue Drives Cardiac Aging Through Modulation of Fibroblast Senescence by Osteopontin Production. Circulation. 2018 Aug 21;138(8):809–22.
Martínez-Martínez E, Jurado-López R, Cervantes-Escalera P, Cachofeiro V, Miana M. Leptin, a mediator of cardiac damage associated with obesity. Horm Mol Biol Clin Investig. 2014 Apr 1;18(1):3–14.
Bosanac J, Straus L, Novaković M, Košuta D, Božič Mijovski M, Tasič J, et al. HFpEF and Atrial Fibrillation: The Enigmatic Interplay of Dysmetabolism, Biomarkers, and Vascular Endothelial Dysfunction. Dis Markers. 2022 Oct 25;2022:1–7.
Zhu T, Chen M, Wang M, Wang Z, Wang S, Hu H, et al. Association between adiponectin‐to‐leptin ratio and heart rate variability in new‐onset paroxysmal atrial fibrillation: A retrospective cohort study. Annals of Noninvasive Electrocardiology. 2022 Mar 2;27(2).
Puchałowicz K, Kłoda K, Dziedziejko V, Rać M, Wojtarowicz A, Chlubek D, et al. Association of Adiponectin, Leptin and Resistin Plasma Concentrations with Echocardiographic Parameters in Patients with Coronary Artery Disease. Diagnostics. 2021 Sep 26;11(10):1774.
Sawaguchi T, Nakajima T, Haruyama A, Hasegawa T, Shibasaki I, Nakajima T, et al. Association of serum leptin and adiponectin concentrations with echocardiographic parameters and pathophysiological states in patients with cardiovascular disease receiving cardiovascular surgery. PLoS One. 2019 Nov 8;14(11):e0225008.
Kamimura D, Suzuki T, Wang W, deShazo M, Hall JE, Winniford MD, et al. Higher plasma leptin levels are associated with reduced left ventricular mass and left ventricular diastolic stiffness in black women: insights from the Genetic Epidemiology Network of Arteriopathy (GENOA) study. Hypertension Research. 2018 Aug 15;41(8):629–38.
Abd alkhaleq H, Kornowski R, Waldman M, Zemel R, Lev DL, Shainberg A, et al. Leptin modulates gene expression in the heart, cardiomyocytes and the adipose tissue thus mitigating LPS-induced damage. Exp Cell Res. 2021 Jul;404(2):112647.
Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Papacosta O, Sattar N. The obesity paradox in men with coronary heart disease and heart failure: The role of muscle mass and leptin. Int J Cardiol. 2014 Jan;171(1):49–55.
McGaffin KR, Witham WG, Yester KA, Romano LC, O’Doherty RM, McTiernan CF, et al. Cardiac-specific leptin receptor deletion exacerbates ischaemic heart failure in mice. Cardiovasc Res. 2011 Jan 1;89(1):60–71.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Krystyna Zabojska, Aleksandra Cygnarowicz, Aneta Klaudia Wojtas, Urszula Korotko, Aneta Mandziuk, Kinga Witowska , Mariola Turemka , Mikolaj Biskupski, Negar Hosseinnejad, Karolina Sacher
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 70
Number of citations: 0
